5 active trials 1 recruiting 2 Phase 3 1 disease areas
| Phase 2 | 3 | |
| Phase 3 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by… | Multiple Myeloma | Active, Not Recruiting | 2026-03-17 |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE… | Multiple Myeloma | Active, Not Recruiting | 2026-02-10 |
| Phase 2 | ||||
| NCT06183489 | Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | Smoldering Multiple Myeloma | Recruiting | 2024-10-18 |
| NCT04564703 | Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients | Multiple Myeloma | Active, Not Recruiting | 2026-07-16 |
| NCT04166565 | Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the… | Multiple Myeloma | Active, Not Recruiting | 2026-04-20 |
Multiple Myeloma (5)